骨改良药物在转移性去势抵抗性前列腺癌中的真实世界使用
该研究利用SEER登记与Medicare理赔链接数据,纳入2007-2015年诊断的IV期前列腺腺癌且接受雄激素剥夺治疗并后续接受去势抵抗性前列腺癌定义治疗(CDT)的男性。在1292例患者中,1034例(80%)有骨转移;有骨转移者在启动CDT后180天内接受骨改良药物(BMA)的比例高于无骨转移者(705/1034[68%] vs 56/258[22%])。无骨转移但骨折高风险者接受BMA的比值比为2.48(95%CI:1.17,5.29),但仅26%的高骨折风险者接受了BMA。
要点
- 有骨转移的mCRPC患者在启动CDT后180天内接受BMA的比例为68%(705/1034),无骨转移者为22%(56/258)。
- 无骨转移但骨折高风险者接受BMA的OR=2.48(95%CI:1.17,5.29),但仅26%接受了BMA。
- 接受BMA的患者中,62%在启动CDT前超过90天即首次启用BMA。
核心结论
- 三分之二的伴有骨转移的mCRPC患者在启动CDT后180天内接受了BMA。
- 更大比例的无骨转移患者可能因预防骨质疏松性骨折而需要BMA治疗。
- 部分有骨转移的患者可能可以将BMA的启动延迟至CRPC阶段。
研究设计与样本
- 研究使用链接的SEER登记与Medicare理赔数据。
- 纳入2007-2015年诊断的IV期前列腺腺癌男性,诊断时年龄>=66岁,在Medicare A、B、D部分有足够连续参保,且接受雄激素剥夺治疗。
- 进一步限定为后续接受CRPC定义治疗(CDT)的患者。
- 通过理赔数据识别有骨转移证据的患者。
- 主要结局为启动CDT后180天内接受BMA(唑来膦酸或地舒单抗)。
主要发现
- 共纳入1292例患者,其中1034例(80%)有骨转移。
- 有骨转移者在启动CDT后180天内接受BMA的比例高于无骨转移者(705/1034[68%] vs 56/258[22%])。
- 无骨转移患者中,骨折高风险者接受BMA的比值比为2.48(95%CI:1.17,5.29),但仅26%的高骨折风险患者接受了BMA。
- 接受BMA的患者中,大多数(62%)在启动CDT前超过90天即首次启用BMA。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Bone modifying agents (BMAs) prevent skeletal related events among patients with metastatic, castration-resistant prostate cancer (mCRPC) involving bone and prevent osteoporotic fractures among patients at high risk. BMA utilization for patients with mCRPC has not been well quantified. METHODS: We used linked SEER registry and Medicare claims data. We included men diagnosed with stage IV prostate adenocarcinoma during 2007-2015, aged > = 66 at diagnosis, with sufficient continuous enrollment in Medicare Parts A, B, and D, who received androgen deprivation therapy. We limited to those who subsequently received a CRPC-defining treatment (CDT). We identified patients with evidence of bone metastasis using claims. Our primary outcome was receipt of a BMA (zoledronic acid or denosumab) within 180 days of initiating CDT. RESULTS: Among 1292 included patients, 1034 (80%) had bone metastasis. BMA use within 180 days of initiating CDT was higher among patients with bone metastases than those without (705/1034 [68%] vs 56/258 [22%]). Among patients without bone metastasis, those with high osteoporotic fracture risk were more likely than those without to receive a BMA (OR = 2.48, 95% CI: 1.17, 5.29); however, only 26% of patients with high fracture risk received a BMA. Among patients who received BMAs, most (62%) first initiated them >90 days before initiating CDT. CONCLUSIONS: Two-thirds of patients with mCRPC and bone metastases received BMAs within 180 days after initiating CDT. A greater proportion of patients without bone metastasis may warrant BMA therapy for osteoporotic fracture prevention. Some patients with bone metastasis may be able to delay BMA initiation until CRPC.
引用
- Mitchell AP, Meza AM, Panageas KS, et al. Real-world use of bone modifying agents in metastatic, castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2022. PMID: 35798857. doi:10.1038/s41391-022-00573-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。